<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<oembed><version>1.0</version><type>rich</type><width>560px</width><height>140px</height><title> The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma</title><url>https://www.myelomasociety.org/the-ifm2017-03-phase-3-trial-a-dexamethasone-sparing-regimen-with-daratumumab-and-lenalidomide-for-frail-patients-with-newly-diagnosed-multiple-myeloma/</url><author_name>IMSound</author_name><author_url>https://www.myelomasociety.org</author_url><thumbnail_url>https://www.myelomasociety.org/wp-content/uploads/2024/07/IMSound-Logo-only-v2.png</thumbnail_url><html>&lt;iframe width="560px" height="140px" src="https://www.myelomasociety.org/the-ifm2017-03-phase-3-trial-a-dexamethasone-sparing-regimen-with-daratumumab-and-lenalidomide-for-frail-patients-with-newly-diagnosed-multiple-myeloma/?standalonePlayer"&gt;&lt;/iframe&gt;</html></oembed>
